Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza B hemagglutinin (HA) is the major surface glycoprotein and principal antigen of the influenza B virus. It plays a critical role in viral entry by binding to host cell receptors and mediating membrane fusion, making it essential for infection and a primary target for neutralizing antibodies. HA exists as a homotrimer, with each monomer composed of two subunits: HA1 (membrane-distal, globular head) and HA2 (membrane-proximal, stem domain).
Antibody neutralization of receptor binding or membrane fusion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza B Hemagglutinin Antigen (HA).